


Lampiran

1. Surat Ijin Etika Penelitian


Fakultas Kedokteran dan Ilmu Kesehatan
Universitas Muhammadiyah Yogyakarta

Nomor : 180/EP-FKIK-UMY/III/2017

KETERANGAN LOLOS UJI ETIK
ETHICAL APPROVAL

Komite Etik Penelitian Fakultas Kedokteran dan Ilmu Kesehatan Universitas Muhammadiyah Yogyakarta dalam upaya melindungi hak asasi dan kesejahteraan responden/subyek penelitian, telah mengkaji dengan teliti protokol berjudul :

The Ethics Committee of the Faculty of Medicine and Health Sciences, University of Muhammadiyah Yogyakarta, with regards of the protection of human rights and welfare in research, has carefully reviewed the research protocol entitled :

“Daya Insulin Mimik Infusa Kayu Manis (*Cinamon burmanii*) Terhadap Penghambatan Kadar IL-6 Pada Tikus Diabetes Strain *Sparague dawley*”


Peneliti Utama : Rahmawati
Principal Investigator

Nama Institusi : Program Studi Pendidikan Dokter FKIK UMY
Name of the Institution

Negara : Indonesia
Country

Dan telah menyetujui protokol tersebut diatas.
And approved the above-mentioned protocol.

Yogyakarta, 29 Maret 2017


 Sekretaris
 Secretary
Dr. dr. Titiek Hidayati, M. Kes

*Peneliti Berkewajiban :

1. Menjaga kerahasiaan identitas subyek penelitian
2. Memberitahukan status penelitian apabila :
 - a. Setelah masa berlakunya keterangan lolos uji etik, penelitian masih belum selesai, dalam hal ini *ethical clearance* harus diperpanjang
 - b. Penelitian berhenti di tengah jalan
3. Melaporkan kejadian serius yang tidak diinginkan (*serious adverse events*)
4. Peneliti tidak boleh melakukan tindakan apapun pada responden/subyek sebelum penelitian lolos uji etik dan *informed consent*

Kampus:

Muda mendunia

Jl. Lingkar Selatan, Tamantirto, Kasihan, Bantul, Yogyakarta 55183
Telp. (0274) 387656 ext. 213, 7491350 Fax. (0274) 387658

2. Data Awal Semua Kelompok

No	Kode sampel	Sebelum Induksi STZ+NA			Setelah induksi STZ+NA		Setelah terapi 1 minggu		Setelah terapi 2 minggu	
		BB (gram)	GDP (mg/dl)	BB(gram)	GDP (mg/dl)	IL-6 (pg/ml)	GDP (mg/dl)	IL-6 (pg/ml)	GDP (mg/dl)	IL-6 (pg/ml)
1	Normal	163	64.31	169	64.32	1834,1	64.66	2024,4	65.33	862,1
2	Normal	165	64.98	172	65.56	1645,58	66.17	816,89	66.06	369,45
3	Normal	166	62.63	171	63.07	998,37	63.91	726,7	64.23	771,7
4	Normal	171	67	179	68.05	1089,66	69.17	592,08	69.34	771,7
5	Normal	168	65.66	175	66.8	1412,11	66.92	998,37	67.88	907,44
6	Diabetes	245	67.68	240	224.90	1598,7	228.2	592,08	229.2	105,08
7	Diabetes	256	68.01	253	231.54	1365,84	231.2	584,56	231.75	442,32
8	Diabetes	183	63.64	179	226.56	962,1	228.2	105,08	230.58	192,8
9	Diabetes	195	66.67	190	231.12	1181,33	232.33	636,86	233.58	369,455
10	Diabetes	244	66.33	239	229.46	1181,33	229.7	862,12	229.93	636,86
11	Glibenklamid	231	69.36	228	233.20	1739,4	146.62	413,81	104.38	1180,31
12	Glibenklamid	180	61.95	177	224.07	1929,05	137.22	192,87	108.76	325,14
13	Glibenklamid	237	66.67	232	226.14	771,75	138.35	1135,45	107.3	681,74
14	Glibenklamid	186	67.68	182	231.12	1043,97	142.86	325,18	110.22	3256,17
15	Glibenklamid	165	70.71	160	231.95	1881,54	143.23	458,24	113.14	458,2
16	Kayu manis 300 mg/kgBB	265	63.64	260	226.14	1043,97	162.41	325,18	117.52	280,99
17	Kayu manis	204	65.99	199	229.05	2216,44	165.04	105,08	120.44	740,52

	300 mg/kgBB									
1 8	Kayu manis 300 mg/kgBB	158	66.6 7	154	230. 71	1645, 58	165. 79	228,2 9	116. 06	547,3
1 9	Kayu manis 300 mg/kgBB	175	67.6 8	172	231. 95	1319, 56	169. 17	192,8 7	119. 71	998,3 6
2 0	Kayu manis 300 mg/kgBB	182	65.6 6	178	232. 78	998,3 7	165. 41	148,9	127. 74	1135, 45
2 1	Kayu manis 150 mg/kgBB	188	67.6 8	185	227. 39	907,4 4	178. 57	458,2 4	145. 26	17,6
2 2	Kayu manis 150 mg/kgBB	230	65.6 6	225	229. 05	1505, 25	180. 45	148,9	148. 54	6,898
2 3	Kayu manis 150 mg/kgBB	168	68.0 1	165	227. 8	1181, 33	177. 07	325,1 8	150	681,7 4
2 4	Kayu manis 150 mg/kgBB	192	64.6 5	189	226. 14	1099, 66	179. 32	148,9	147. 08	502,7 7
2 5	Kayu manis 150 mg/kgBB	180	66.3 3	175	229. 46	1365, 84	181. 2	299	145. 62	1739, 64

3. Hasil Uji Statistik

- a. Uji statistic gula darah sebelum, sesudah induksi Steptozotocin dan setelah pemberian terapi.

Descriptives			Statistic	Std. Error	
Kelompok					
glukosa_pre_stz	normal	Mean	64.9160	.72435	
		95% Confidence Interval for Mean	Lower Bound	62.9049	
			Upper Bound	66.9271	
		5% Trimmed Mean	64.9272		
		Median	64.9800		
		Variance	2.623		
		Std. Deviation	1.61970		
		Minimum	62.63		
		Maximum	67.00		
		Range	4.37		
		Interquartile Range	2.86		
		Skewness	-.265	.913	
		Kurtosis	.466	2.000	
		dm		Mean	66.4660
95% Confidence Interval for Mean	Lower Bound			64.3240	
	Upper Bound			68.6080	
5% Trimmed Mean	66.5372				
Median	66.6700				
Variance	2.976				
Std. Deviation	1.72512				
Minimum	63.64				
Maximum	68.01				
Range	4.37				
Interquartile Range	2.86				

	Skewness		-1.387	.913
	Kurtosis		2.111	2.000
glibenkla	Mean		67.2740	1.50054
mid	95% Confidence Interval for	Lower Bound	63.1078	
	Mean	Upper Bound	71.4402	
	5% Trimmed Mean		67.3789	
	Median		67.6800	
	Variance		11.258	
	Std. Deviation		3.35530	
	Minimum		61.95	
	Maximum		70.71	
	Range		8.76	
	Interquartile Range		5.72	
	Skewness		-1.119	.913
	Kurtosis		1.487	2.000
dosis 300	Mean		65.9280	.66823
	95% Confidence Interval for	Lower Bound	64.0727	
	Mean	Upper Bound	67.7833	
	5% Trimmed Mean		65.9578	
	Median		65.9900	
	Variance		2.233	
	Std. Deviation		1.49421	
	Minimum		63.64	
	Maximum		67.68	
	Range		4.04	
	Interquartile Range		2.53	
	Skewness		-.776	.913
	Kurtosis		1.312	2.000
dosis 150	Mean		66.4660	.62545
		Lower Bound	64.7295	

	95% Confidence Interval for Mean	Upper Bound	68.2025	
	5% Trimmed Mean		66.4811	
	Median		66.3300	
	Variance		1.956	
	Std. Deviation		1.39855	
	Minimum		64.65	
	Maximum		68.01	
	Range		3.36	
	Interquartile Range		2.69	
	Skewness		-.159	.913
	Kurtosis		-1.742	2.000
glukosa_postSTZ _sebelum_terapi	Mean		65.5600	.87964
	95% Confidence Interval for Mean	Lower Bound	63.1177	
		Upper Bound	68.0023	
	5% Trimmed Mean		65.5600	
	Median		65.5600	
	Variance		3.869	
	Std. Deviation		1.96694	
	Minimum		63.07	
	Maximum		68.05	
	Range		4.98	
	Interquartile Range		3.73	
	Skewness		.000	.913
	Kurtosis		-1.185	2.000
dm	Mean		2.2872E2	1.29456
	95% Confidence Interval for Mean	Lower Bound	2.2512E2	
		Upper Bound	2.3231E2	
	5% Trimmed Mean		2.2877E2	
	Median		2.2946E2	
	Variance		8.379	

	Std. Deviation		2.89473	
	Minimum		224.90	
	Maximum		231.54	
	Range		6.64	
	Interquartile Range		5.60	
	Skewness		-.494	.913
	Kurtosis		-2.108	2.000
glibenkla	Mean		2.2930E2	1.77318
mid	95% Confidence Interval for	Lower Bound	2.2437E2	
	Mean	Upper Bound	2.3422E2	
	5% Trimmed Mean		2.2937E2	
	Median		2.3112E2	
	Variance		15.721	
	Std. Deviation		3.96495	
	Minimum		224.07	
	Maximum		233.20	
	Range		9.13	
	Interquartile Range		7.47	
	Skewness		-.601	.913
	Kurtosis		-2.244	2.000
dosis 300	Mean		2.3013E2	1.17809
	95% Confidence Interval for	Lower Bound	2.2686E2	
	Mean	Upper Bound	2.3340E2	
	5% Trimmed Mean		2.3020E2	
	Median		2.3071E2	
	Variance		6.939	
	Std. Deviation		2.63428	
	Minimum		226.14	
	Maximum		232.78	
	Range		6.64	
	Interquartile Range		4.77	
	Skewness		-.903	.913

	Kurtosis		.166	2.000
dosis 150	Mean		2.2797E2	.59585
	95% Confidence Interval for Mean	Lower Bound	2.2631E2	
		Upper Bound	2.2962E2	
	5% Trimmed Mean		2.2799E2	
	Median		2.2780E2	
	Variance		1.775	
	Std. Deviation		1.33236	
	Minimum		226.14	
	Maximum		229.46	
	Range		3.32	
	Interquartile Range		2.49	
	Skewness		-.303	.913
	Kurtosis		-1.017	2.000
glukosa_1minggu normal	Mean		66.1660	.92060
	95% Confidence Interval for Mean	Lower Bound	63.6100	
		Upper Bound	68.7220	
	5% Trimmed Mean		66.1244	
	Median		66.1700	
	Variance		4.238	
	Std. Deviation		2.05853	
	Minimum		63.91	
	Maximum		69.17	
	Range		5.26	
	Interquartile Range		3.76	
	Skewness		.604	.913
	Kurtosis		-.148	2.000
dm	Mean		2.2993E2	.81889
	95% Confidence Interval for Mean	Lower Bound	2.2765E2	
		Upper Bound	2.3220E2	
	5% Trimmed Mean		2.2989E2	
	Median		2.2970E2	

	Variance		3.353	
	Std. Deviation		1.83109	
	Minimum		228.20	
	Maximum		232.33	
	Range		4.13	
	Interquartile Range		3.56	
	Skewness		.385	.913
	Kurtosis		-2.019	2.000
<hr/>				
glibenkla	Mean		1.4166E2	1.72012
mid	95% Confidence Interval for	Lower Bound	1.3688E2	
	Mean	Upper Bound	1.4643E2	
	5% Trimmed Mean		1.4163E2	
	Median		1.4286E2	
	Variance		14.794	
	Std. Deviation		3.84630	
	Minimum		137.22	
	Maximum		146.62	
	Range		9.40	
	Interquartile Range		7.14	
	Skewness		.033	.913
	Kurtosis		-1.591	2.000
<hr/>				
dosis 300	Mean		1.6556E2	1.07936
	95% Confidence Interval for	Lower Bound	1.6257E2	
	Mean	Upper Bound	1.6856E2	
	5% Trimmed Mean		1.6554E2	
	Median		1.6541E2	
	Variance		5.825	
	Std. Deviation		2.41352	
	Minimum		162.41	
	Maximum		169.17	
	Range		6.76	
	Interquartile Range		3.75	

	Skewness		.456	.913
	Kurtosis		1.877	2.000
dosis 150	Mean		1.7932E2	.72237
	95% Confidence Interval for Mean	Lower Bound	1.7732E2	
		Upper Bound	1.8133E2	
	5% Trimmed Mean		1.7934E2	
	Median		1.7932E2	
	Variance		2.609	
	Std. Deviation		1.61526	
	Minimum		177.07	
	Maximum		181.20	
	Range		4.13	
	Interquartile Range		3.00	
	Skewness		-.374	.913
	Kurtosis		-.637	2.000
glukosa_2minggu	normal	Mean	66.5680	.91275
		95% Confidence Interval for Mean	Lower Bound	64.0338
			Upper Bound	69.1022
		5% Trimmed Mean	66.5439	
		Median	66.0600	
		Variance	4.166	
		Std. Deviation	2.04097	
		Minimum	64.23	
		Maximum	69.34	
		Range	5.11	
		Interquartile Range	3.83	
		Skewness	.429	.913
		Kurtosis	-1.207	2.000
dm	Mean		2.3101E2	.76746
	95% Confidence Interval for Mean	Lower Bound	2.2888E2	
		Upper Bound	2.3314E2	
	5% Trimmed Mean		2.3097E2	

	Median		2.3058E2	
	Variance		2.945	
	Std. Deviation		1.71609	
	Minimum		229.20	
	Maximum		233.58	
	Range		4.38	
	Interquartile Range		3.10	
	Skewness		.839	.913
	Kurtosis		.090	2.000
glibenkla	Mean		1.0876E2	1.46000
mid	95% Confidence Interval for	Lower Bound	1.0471E2	
	Mean	Upper Bound	1.1281E2	
	5% Trimmed Mean		1.0876E2	
	Median		1.0876E2	
	Variance		10.658	
	Std. Deviation		3.26466	
	Minimum		104.38	
	Maximum		113.14	
	Range		8.76	
	Interquartile Range		5.84	
	Skewness		.000	.913
	Kurtosis		.200	2.000
dosis 300	Mean		1.2029E2	2.01776
	95% Confidence Interval for	Lower Bound	1.1469E2	
	Mean	Upper Bound	1.2590E2	
	5% Trimmed Mean		1.2012E2	
	Median		1.1971E2	
	Variance		20.357	
	Std. Deviation		4.51185	
	Minimum		116.06	
	Maximum		127.74	
	Range		11.68	

	Interquartile Range		7.30	
	Skewness		1.431	.913
	Kurtosis		2.421	2.000
dosis 150	Mean		1.4730E2	.89051
	95% Confidence Interval for Mean	Lower Bound	1.4483E2	
		Upper Bound	1.4977E2	
	5% Trimmed Mean		1.4726E2	
	Median		1.4708E2	
	Variance		3.965	
	Std. Deviation		1.99123	
	Minimum		145.26	
	Maximum		150.00	
	Range		4.74	
	Interquartile Range		3.83	
	Skewness		.441	.913
	Kurtosis		-1.576	2.000

Tests of Normality

kelompok	Kolmogorov-Smirnov ^a			Shapiro-Wilk			
	Statistic	df	Sig.	Statistic	df	Sig.	
glukosa_pre_stz	normal	.154	5	.200*	.994	5	.993
	dm	.269	5	.200*	.877	5	.294
	glibenklamid	.229	5	.200*	.930	5	.596
	dosis 300	.229	5	.200*	.961	5	.812
	dosis 150	.207	5	.200*	.946	5	.710
glukosa_postSTZ _sebelum_terapi	normal	.136	5	.200*	.987	5	.969
	dm	.201	5	.200*	.907	5	.450
	glibenklamid	.277	5	.200*	.887	5	.345
	dosis 300	.188	5	.200*	.942	5	.679
	dosis 150	.192	5	.200*	.957	5	.789
glukosa_1minggu	normal	.168	5	.200*	.964	5	.833
	dm	.227	5	.200*	.897	5	.395
	glibenklamid	.223	5	.200*	.932	5	.608
	dosis 300	.263	5	.200*	.938	5	.649
	dosis 150	.158	5	.200*	.980	5	.937
glukosa_2minggu	normal	.198	5	.200*	.966	5	.848
	dm	.198	5	.200*	.953	5	.758
	glibenklamid	.127	5	.200*	.999	5	1.000
	dosis 300	.287	5	.200*	.881	5	.312
	dosis 150	.201	5	.200*	.937	5	.645

a. Lilliefors Significance

Correction

*. This is a lower bound of the true significance.

Test of Homogeneity of Variances

	Levene Statistic	df1	df2	Sig.
glukosa_pre_stz	1.026	4	20	.418
glukosa_postSTZ_sebelum_t erapi	3.157	4	20	.036
glukosa_1minggu	1.680	4	20	.194
glukosa_2minggu	.809	4	20	.534

Paired Samples Statistics

	Mean	N	Std. Deviation	Std. Error Mean
Pair 1 glukosa_preSTZ	66.5335	20	2.03018	.45396
Glukosa_postSTZ	2.2903E2	20	2.75061	.61506

Paired Samples Correlations

	N	Correlation	Sig.
Pair 1 glukosa_preSTZ & Glukosa_postSTZ	20	.616	.004

Paired Samples Test

	Paired Differences					t	df	Sig. (2-tailed)
	Mean	Std. Deviation	Std. Error Mean	95% Confidence Interval of the Difference				
				Lower	Upper			
Pair 1 glukosa_preSTZ - Glukosa_postSTZ	-1.62493E2	2.19336	.49045	-163.51953	-161.46647	331.313	19	.000

ANOVA

		Sum of Squares	df	Mean Square	F	Sig.
glukosa_pre_stz	Between Groups	15.086	4	3.771	.896	.485
	Within Groups	84.184	20	4.209		
	Total	99.270	24			
glukosa_postSTZ _sebelum_terapi	Between Groups	106897.678	4	26724.420	3.643E3	.000
	Within Groups	146.735	20	7.337		
	Total	107044.413	24			
glukosa_1minggu	Between Groups	71874.748	4	17968.687	2.915E3	.000
	Within Groups	123.274	20	6.164		
	Total	71998.022	24			
glukosa_2minggu	Between Groups	74781.699	4	18695.425	2.221E3	.000
	Within Groups	168.361	20	8.418		
	Total	74950.060	24			

3. Uji statistik interleukin-6 sebelum, dan setelah pemberian terapi

Descriptives

	KELOMPOK		Statistic	Std. Error
P1	NORMAL	Mean	1395,9640	159,12811
		95% Confidence Interval for Mean		
		Lower Bound	954,1535	
		Upper Bound	1837,7745	
		5% Trimmed Mean	1393,7117	
		Median	1412,1100	
		Variance	126608,781	
		Std. Deviation	355,82128	
		Minimum	998,37	
		Maximum	1834,10	
		Range	835,73	
		Interquartile Range	695,82	
		Skewness	,075	,913
		Kurtosis	-2,189	2,000

DM	Mean		1257,8600	106,54089
	95% Confidence Interval for Mean	Lower Bound	962,0551	
		Upper Bound	1553,6649	
	5% Trimmed Mean		1255,3556	
	Median		1181,3300	
	Variance		56754,811	
	Std. Deviation		238,23268	
	Minimum		962,10	
	Maximum		1598,70	
	Range		636,60	
	Interquartile Range		410,56	
	Skewness		,434	,913
	Kurtosis		,286	2,000
	GLIBENKLAMID	Mean		1473,1420
95% Confidence Interval for Mean		Lower Bound	815,6244	
		Upper Bound	2130,6596	
5% Trimmed Mean			1486,7800	
Median			1739,4000	
Variance			280418,424	
Std. Deviation			529,54549	
Minimum			771,75	
Maximum			1929,05	
Range			1157,30	
Interquartile Range			997,44	
Skewness			-,680	,913
Kurtosis			-2,405	2,000
INFUSA 300		Mean		1444,7840
	95% Confidence Interval for Mean	Lower Bound	820,4263	
		Upper Bound	2069,1417	
	5% Trimmed Mean		1426,7150	
	Median		1319,5600	
	Variance		252847,597	
	Std. Deviation		502,83953	
	Minimum		998,37	
	Maximum		2216,44	

		Range	1218,07	
		Interquartile Range	909,84	
		Skewness	1,023	,913
		Kurtosis	,250	2,000
	INFUSA150	Mean	1211,9040	103,91823
		95% Confidence Interval for Mean	Lower Bound 923,3807 Upper Bound 1500,4273	
		5% Trimmed Mean	1212,5217	
		Median	1181,3300	
		Variance	53994,995	
		Std. Deviation	232,36823	
		Minimum	907,44	
		Maximum	1505,25	
		Range	597,81	
		Interquartile Range	432,00	
		Skewness	-,026	,913
		Kurtosis	-,832	2,000
P2	NORMAL	Mean	1031,6880	256,80715
		95% Confidence Interval for Mean	Lower Bound 318,6770 Upper Bound 1744,6990	
		5% Trimmed Mean	1000,9600	
		Median	816,8900	
		Variance	329749,565	
		Std. Deviation	574,23825	
		Minimum	592,08	
		Maximum	2024,40	
		Range	1432,32	
		Interquartile Range	851,99	
		Skewness	1,881	,913
		Kurtosis	3,718	2,000
	DM	Mean	556,1400	123,63130
		95% Confidence Interval for Mean	Lower Bound 212,8845 Upper Bound 899,3955	
		5% Trimmed Mean	564,2000	
		Median	592,0800	
		Variance	76423,496	

	Std. Deviation		276,44800	
	Minimum		105,08	
	Maximum		862,12	
	Range		757,04	
	Interquartile Range		404,67	
	Skewness		-1,233	,913
	Kurtosis		2,745	2,000
GLIBENKLAMID	Mean		505,1100	163,97098
	95% Confidence Interval for Mean	Lower Bound	49,8536	
		Upper Bound	960,3664	
	5% Trimmed Mean		487,4378	
	Median		413,8100	
	Variance		134432,406	
	Std. Deviation		366,65025	
	Minimum		192,87	
	Maximum		1135,45	
	Range		942,58	
	Interquartile Range		537,82	
	Skewness		1,803	,913
	Kurtosis		3,655	2,000
INFUSA 300	Mean		200,0640	37,51146
	95% Confidence Interval for Mean	Lower Bound	95,9155	
		Upper Bound	304,2125	
	5% Trimmed Mean		198,3900	
	Median		192,8700	
	Variance		7035,547	
	Std. Deviation		83,87817	
	Minimum		105,08	
	Maximum		325,18	
	Range		220,10	
	Interquartile Range		149,75	
	Skewness		,699	,913
	Kurtosis		,433	2,000
INFUSA150	Mean		276,0440	58,50979
	95% Confidence Interval for Mean	Lower Bound	113,5948	
		Upper Bound	438,4932	
	5% Trimmed Mean		272,9856	

		Median	299,0000	
		Variance	17116,975	
		Std. Deviation	130,83186	
		Minimum	148,90	
		Maximum	458,24	
		Range	309,34	
		Interquartile Range	242,81	
		Skewness	,385	,913
		Kurtosis	-1,043	2,000
P3	NORMAL	Mean	736,4780	95,44622
		95% Confidence Interval for Mean	Lower Bound 471,4768 Upper Bound 1001,4792	
		5% Trimmed Mean	747,3706	
		Median	771,7000	
		Variance	45549,906	
		Std. Deviation	213,42424	
		Minimum	369,45	
		Maximum	907,44	
		Range	537,99	
		Interquartile Range	314,19	
		Skewness	-1,816	,913
		Kurtosis	3,599	2,000
	DM	Mean	349,3030	93,77776
		95% Confidence Interval for Mean	Lower Bound 88,9342 Upper Bound 609,6718	
		5% Trimmed Mean	346,8956	
		Median	369,4550	
		Variance	43971,339	
		Std. Deviation	209,69344	
		Minimum	105,08	
		Maximum	636,86	
		Range	531,78	
		Interquartile Range	390,65	
		Skewness	,280	,913
		Kurtosis	-,843	2,000
	GLIBENKLAMID	Mean	1180,3120	539,00489

	95% Confidence Interval for Mean	Lower Bound	-316,2055	
		Upper Bound	2676,8295	
	5% Trimmed Mean		1112,4961	
	Median		681,7400	
	Variance		1452631,341	
	Std. Deviation		1205,25157	
	Minimum		325,14	
	Maximum		3256,17	
	Range		2931,03	
	Interquartile Range		1826,57	
	Skewness		1,861	,913
	Kurtosis		3,514	2,000
INFUSA 300	Mean		740,5240	153,45243
	95% Confidence Interval for Mean	Lower Bound	314,4718	
		Upper Bound	1166,5762	
	5% Trimmed Mean		744,1133	
	Median		740,5200	
	Variance		117738,240	
	Std. Deviation		343,13006	
	Minimum		280,99	
	Maximum		1135,45	
	Range		854,46	
	Interquartile Range		652,76	
	Skewness		-,263	,913
	Kurtosis		-1,261	2,000
INFUSA150	Mean		589,7296	316,65018
	95% Confidence Interval for Mean	Lower Bound	-289,4323	
		Upper Bound	1468,8915	
	5% Trimmed Mean		558,2252	
	Median		502,7700	
	Variance		501336,692	
	Std. Deviation		708,05133	
	Minimum		6,90	
	Maximum		1739,64	
	Range		1732,74	

Interquartile Range	1198,44	
Skewness	1,333	,913
Kurtosis	1,803	2,000

Tests of Normality

	KELOMPOK	Kolmogorov-Smirnov ^a			Shapiro-Wilk		
		Statistic	df	Sig.	Statistic	df	Sig.
P1	NORMAL	,205	5	,200*	,939	5	,660
	DM	,226	5	,200*	,963	5	,831
	GLIBENKLAMID	,292	5	,188	,841	5	,168
	INFUSA 300	,198	5	,200*	,901	5	,417
	INFUSA150	,152	5	,200*	,986	5	,966
P2	NORMAL	,323	5	,096	,785	5	,061
	DM	,341	5	,058	,870	5	,267
	GLIBENKLAMID	,351	5	,044	,807	5	,092
	INFUSA 300	,168	5	,200*	,973	5	,892
	INFUSA150	,234	5	,200*	,899	5	,406
P3	NORMAL	,366	5	,028	,790	5	,067
	DM	,172	5	,200*	,973	5	,894
	GLIBENKLAMID	,300	5	,161	,775	5	,050
	INFUSA 300	,174	5	,200*	,973	5	,891
	INFUSA150	,248	5	,200*	,858	5	,222

*. This is a lower bound of the true significance.

a. Lilliefors Significance Correction

Test of Homogeneity of Variances

	Levene Statistic	df1	df2	Sig.
P1	2,583	4	20	,068
P2	1,926	4	20	,145
P3	2,460	4	20	,079

ANOVA

		Sum of Squares	df	Mean Square	F	Sig.
P1	Between Groups	267972,073	4	66993,018	,435	,782
	Within Groups	3082498,435	20	154124,922		

	Total	3350470,508	24			
P2	Between Groups	2125171,825	4	531292,956	4,704	,008
	Within Groups	2259031,956	20	112951,598		
	Total	4384203,781	24			
P3	Between Groups	1834819,349	4	458704,837	1,061	,401
	Within Groups	8644910,072	20	432245,504		
	Total	10479729,421	24			

Post Hoc Tests

Multiple Comparisons

LSD

Dependent Variable	(I) KELOMPOK	(J) KELOMPOK	Mean Difference (I-J)	Std. Error	Sig.	95% Confidence Interval	
						Lower Bound	Upper Bound
P1	NORMAL	DM	138,10400	248,29412	,584	-379,8285	656,0365
		GLIBENKLA MID	-77,17800	248,29412	,759	-595,1105	440,7545
		INFUSA 300	-48,82000	248,29412	,846	-566,7525	469,1125
		INFUSA150	184,06000	248,29412	,467	-333,8725	701,9925
	DM	NORMAL	-138,10400	248,29412	,584	-656,0365	379,8285
		GLIBENKLA MID	215,28200	248,29412	,396	-733,2145	302,6505
		INFUSA 300	186,92400	248,29412	,460	-704,8565	331,0085
		INFUSA150	45,95600	248,29412	,855	-471,9765	563,8885
	GLIBENKLA MID	NORMAL	77,17800	248,29412	,759	-440,7545	595,1105
		DM	215,28200	248,29412	,396	-302,6505	733,2145

		INFUSA 300	28,35800	248,294 12	,9 10	-489,5745	546,2905
		INFUSA150	261,2380 0	248,294 12	,3 05	-256,6945	779,1705
		INFUSA 300 NORMAL	48,82000	248,294 12	,8 46	-469,1125	566,7525
		DM	186,9240 0	248,294 12	,4 60	-331,0085	704,8565
		GLIBENKLA MID	-28,35800	248,294 12	,9 10	-546,2905	489,5745
		INFUSA150	232,8800 0	248,294 12	,3 59	-285,0525	750,8125
		INFUSA150 NORMAL	- 184,0600 0	248,294 12	,4 67	-701,9925	333,8725
		DM	-45,95600	248,294 12	,8 55	-563,8885	471,9765
		GLIBENKLA MID	- 261,2380 0	248,294 12	,3 05	-779,1705	256,6945
		INFUSA 300	- 232,8800 0	248,294 12	,3 59	-750,8125	285,0525
P2		NORMAL DM	475,5480 0*	212,557 38	,0 37	32,1611	918,9349
		GLIBENKLA MID	526,5780 0*	212,557 38	,0 22	83,1911	969,9649
		INFUSA 300	831,6240 0*	212,557 38	,0 01	388,2371	1275,0109
		INFUSA150	755,6440 0*	212,557 38	,0 02	312,2571	1199,0309
		DM NORMAL	- 475,5480 0*	212,557 38	,0 37	-918,9349	-32,1611
		GLIBENKLA MID	51,03000	212,557 38	,8 13	-392,3569	494,4169
		INFUSA 300	356,0760 0	212,557 38	,1 09	-87,3109	799,4629

		INFUSA150	280,0960 0	212,557 38	,2 02	-163,2909	723,4829
	GLIBENKLA MID	NORMAL	- 526,5780 0*	212,557 38	,0 22	-969,9649	-83,1911
		DM	-51,03000	212,557 38	,8 13	-494,4169	392,3569
		INFUSA 300	305,0460 0	212,557 38	,1 67	-138,3409	748,4329
		INFUSA150	229,0660 0	212,557 38	,2 94	-214,3209	672,4529
	INFUSA 300 MID	NORMAL	- 831,6240 0*	212,557 38	,0 01	- 1275,0109	-388,2371
		DM	- 356,0760 0	212,557 38	,1 09	-799,4629	87,3109
	GLIBENKLA MID		- 305,0460 0	212,557 38	,1 67	-748,4329	138,3409
		INFUSA150	-75,98000	212,557 38	,7 24	-519,3669	367,4069
	INFUSA150 MID	NORMAL	- 755,6440 0*	212,557 38	,0 02	- 1199,0309	-312,2571
		DM	- 280,0960 0	212,557 38	,2 02	-723,4829	163,2909
	GLIBENKLA MID		- 229,0660 0	212,557 38	,2 94	-672,4529	214,3209
		INFUSA 300	75,98000	212,557 38	,7 24	-367,4069	519,3669
P3	NORMAL	DM	387,1750 0	415,810 30	,3 63	-480,1901	1254,5401
		GLIBENKLA MID	- 443,8340 0	415,810 30	,2 99	- 1311,1991	423,5311

	INFUSA 300	-4,04600	415,810 30	,9 92	-871,4111	863,3191
	INFUSA150	146,7484 0	415,810 30	,7 28	-720,6167	1014,1135
DM	NORMAL	- 387,1750 0	415,810 30	,3 63	- 1254,5401	480,1901
	GLIBENKLA MID	- 831,0090 0	415,810 30	,0 59	- 1698,3741	36,3561
	INFUSA 300	- 391,2210 0	415,810 30	,3 58	- 1258,5861	476,1441
	INFUSA150	- 240,4266 0	415,810 30	,5 70	- 1107,7917	626,9385
GLIBENKLA MID	NORMAL	443,8340 0	415,810 30	,2 99	-423,5311	1311,1991
	DM	831,0090 0	415,810 30	,0 59	-36,3561	1698,3741
	INFUSA 300	439,7880 0	415,810 30	,3 03	-427,5771	1307,1531
	INFUSA150	590,5824 0	415,810 30	,1 71	-276,7827	1457,9475
INFUSA 300	NORMAL	4,04600	415,810 30	,9 92	-863,3191	871,4111
	DM	391,2210 0	415,810 30	,3 58	-476,1441	1258,5861
	GLIBENKLA MID	- 439,7880 0	415,810 30	,3 03	- 1307,1531	427,5771
	INFUSA150	150,7944 0	415,810 30	,7 21	-716,5707	1018,1595
INFUSA150	NORMAL	- 146,7484 0	415,810 30	,7 28	- 1014,1135	720,6167
	DM	240,4266 0	415,810 30	,5 70	-626,9385	1107,7917

GLIBENKLA	-	415,810	,1	-	
MID	590,5824	30	71	1457,9475	276,7827
	0				
INFUSA 300	-	415,810	,7	-	
	150,7944	30	21	1018,1595	716,5707
	0				

*. The mean difference is significant at the 0.05 level.

4. Gambar proses penelitian



Gambar 6. Persiapan bahan induksi

Gambar 7. Tikus diinduksi dengan STZ+NA




Gambar 8. Pengambil darah melalui vena orbita tikus




Gambar 9. Darah disentrifuse dengan kecepatan 4000 rpm 15 menit untuk diambil serum nya





Gambar 11. Proses pembuatan infusa kayu manis



Gambar 12. Proses pemeriksaan IL-6 menggunakan metode ELISA dengan pembacaan menggunakan microplate reader O.D 450 nm

5. Penghitungan dosis

a. induksi STZ+NA

Strain*	Weight (g)/ age at time of diabetes induction	Fasting state before diabetes induction	NA dose (mg/kg)	STZ dose (mg/kg)	Time between NA and STZ injection (min)	Time of blood glucose test after diabetes induction/ fasted or non-fasted	Glucose levels (mg/dL) to be considered diabetics	Reference
Wistar	200–220/NR	Overnight	110 i.p.	45 i.p.	15	30 days/ fasted	262 ± 16 (mean ± SD)	(57)
Wistar	NR/2–3 months	NR	210 i.p.	60 i.v.	15	2 weeks/NR	149 ± 3.6	(37)
Wistar	250–300/NR	NR	200 i.p.	60 i.v.	15	NR	> 180	(22)
Sprague-Dawley	NR/8–10 weeks	Overnight	120 i.p.	60 i.v.	15	3 and 7 days/NR	238 ± 14.4	(74)
Wistar	180–220 g/8 weeks	Overnight	110 i.p.	65 i.p.	15	72 h and 7 days/NR	200	(44)
Wistar	NR/2 months	NR	180 i.p.	50 i.v.	30	8 weeks/NR	159.6 ± 23.8 (mean ± SD)	(18)
Wistar	NR/2–3 months	NR	270 i.p.	60 i.v.	15	5–8 weeks/ non-fasted	151 ± 7.5	(47)
Wistar	220–240/10 weeks	NR	260 i.p.	65 i.v.	15	15 days/NR	140–200	(36)
Wistar	220–230/ 2.5 months	NR	270 i.p.	60 i.v.	15	2 weeks/NR	137 ± 3 (mean ± SEM)	(26)
Wistar	NR/2–3 months	NR	290 i.p.	60 i.v.	15	3–5 weeks/ non-fasted	150–180	(46)
Wistar	220–230/10 weeks	NR	230 i.p.	65 i.v.	15	3 weeks/NR	163 ± 4 (mean ± SEM)	(15)
Wistar	180–220/NR	Overnight	110 i.p.	45 i.p.	15	3 days/	> 250	(59)

b. Pemberian terapi Glibenklamid

Dosis *glibenclamide* untuk manusia 70 kg: 5 mg

Nilai konversi dosis dari manusia 70 kg kepada tikus 200 g: 0,018

Dosis untuk 200 g tikus: 5 mg x 0,018 = 0,09 mg/200 gBB